Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Sebastian Schneeweiss, Sc.D., M.D.

Co-Author

This page shows the publications co-authored by Sebastian Schneeweiss and Alec Walker.
Connection Strength

2.545
  1. Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study. J Antimicrob Chemother. 2016 10; 71(10):2938-44.
    View in: PubMed
    Score: 0.670
  2. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med. 2008 Feb 21; 358(8):771-83.
    View in: PubMed
    Score: 0.374
  3. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CMAJ. 2002 Mar 19; 166(6):737-45.
    View in: PubMed
    Score: 0.248
  4. Removal of ineligible outcome cases reduces confounding. Clin Epidemiol. 2018; 10:575-579.
    View in: PubMed
    Score: 0.190
  5. Reuse of data sources to evaluate drug safety signals: When is it appropriate? Pharmacoepidemiol Drug Saf. 2018 06; 27(6):567-569.
    View in: PubMed
    Score: 0.190
  6. Sequential surveillance for drug safety in a regulatory environment. Pharmacoepidemiol Drug Saf. 2018 07; 27(7):707-712.
    View in: PubMed
    Score: 0.188
  7. Characteristics of study design and elements that may contribute to the success of electronic safety monitoring systems. Pharmacoepidemiol Drug Saf. 2014 Nov; 23(11):1223-5.
    View in: PubMed
    Score: 0.148
  8. Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules. Epidemiology. 2012 Mar; 23(2):238-46.
    View in: PubMed
    Score: 0.124
  9. An event-based approach for comparing the performance of methods for prospective medical product monitoring. Pharmacoepidemiol Drug Saf. 2012 Jun; 21(6):631-9.
    View in: PubMed
    Score: 0.122
  10. Effect of aprotinin on renal dysfunction. Lancet. 2008 Jul 05; 372(9632):26; author reply 26-7.
    View in: PubMed
    Score: 0.096
  11. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin Pharmacol Ther. 2003 Oct; 74(4):388-400.
    View in: PubMed
    Score: 0.069
  12. Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance. J Clin Epidemiol. 2002 Aug; 55(8):833-41.
    View in: PubMed
    Score: 0.064
  13. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med. 2002 Mar 14; 346(11):822-9.
    View in: PubMed
    Score: 0.062
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.